High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy
- PMID: 17184556
- PMCID: PMC1797031
- DOI: 10.1186/bcr1619
High-throughput genomic technology in research and clinical management of breast cancer. Plasma-based proteomics in early detection and therapy
Abstract
Protein-based breast cancer biomarkers are a promising resource for breast cancer detection at the earliest and most treatable stages of the disease. Plasma is well suited to proteomic-based methods of biomarker discovery because it is easily obtained, is routinely used in the diagnosis of many diseases, and has a rich proteome. However, due to the vast dynamic range in protein concentration and the often uncertain tissue and cellular origin of plasma proteins, proteomic analysis of plasma requires special consideration compared with tissue and cultured cells. This review briefly touches on the search for plasma-based protein biomarkers for the early detection and treatment of breast cancer.
Similar articles
-
Clinical proteomics in breast cancer: a review.Breast Cancer Res Treat. 2009 Jul;116(1):17-29. doi: 10.1007/s10549-008-0263-3. Epub 2008 Dec 11. Breast Cancer Res Treat. 2009. PMID: 19082706 Review.
-
Proteomics: new technologies and clinical applications.Eur J Cancer. 2008 Dec;44(18):2737-41. doi: 10.1016/j.ejca.2008.09.007. Epub 2008 Nov 1. Eur J Cancer. 2008. PMID: 18977654 Review.
-
Proteomic approaches for serum biomarker discovery in cancer.Anticancer Res. 2007 May-Jun;27(3A):1247-55. Anticancer Res. 2007. PMID: 17593616 Review.
-
The evolving role of proteomics in the early detection of breast cancer.Int J Fertil Womens Med. 2005 Sep-Oct;50(5 Pt 1):212-6. Int J Fertil Womens Med. 2005. PMID: 16468471 Review.
-
Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis.Cancer Lett. 2005 Dec 18;230(2):187-98. doi: 10.1016/j.canlet.2004.12.017. Epub 2005 Jan 18. Cancer Lett. 2005. PMID: 16297705 Review.
Cited by
-
Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer.Invest Ophthalmol Vis Sci. 2015 Mar 9;56(3):1680-8. doi: 10.1167/iovs.14-15739. Invest Ophthalmol Vis Sci. 2015. PMID: 25754855 Free PMC article.
-
Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening.Br J Cancer. 2010 Feb 2;102(3):462-8. doi: 10.1038/sj.bjc.6605511. Epub 2010 Jan 12. Br J Cancer. 2010. PMID: 20068563 Free PMC article.
-
Molecular targets of alcohol action: Translational research for pharmacotherapy development and screening.Prog Mol Biol Transl Sci. 2011;98:293-347. doi: 10.1016/B978-0-12-385506-0.00007-7. Prog Mol Biol Transl Sci. 2011. PMID: 21199775 Free PMC article. Review.
-
Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.J Hematol Oncol. 2010 Apr 7;3:13. doi: 10.1186/1756-8722-3-13. J Hematol Oncol. 2010. PMID: 20374647 Free PMC article. Review.
-
Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer.PLoS One. 2010 Dec 31;5(12):e15573. doi: 10.1371/journal.pone.0015573. PLoS One. 2010. PMID: 21217834 Free PMC article.
References
-
- American Cancer Society After the Tests: Staging http://www.cancer.org/docroot/CRI/content/CRI_2_2_3X_After_ the_tests_St...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical